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O B J E C T I V E S This study sought to analyze the natural history of coronary atherosclerosis by
multislice computed tomography (MSCT) and assess the serial changes in coronary plaque burden,
lumen dimensions, and arterial remodeling.
B A C KG ROUND MSCT can comprehensively assess coronary atherosclerosis by combining lumen
and plaque size parameters.
METHOD S Thirty-two patients with acute coronary syndromes underwent 64-slice computed
tomography angiography after percutaneous coronary intervention at baseline and after a median of 39
months. All patients received contemporary medical treatment. All available coronary segments in every
subject were analyzed. The progression of atherosclerosis per segment and per patient was assessed by
means of change in percent atheroma volume (PAV), change in normalized total atheroma volume
(TAVnorm), and percent change in TAV (% change in TAV). Serial coronary remodeling was also assessed.
Measures of lumen stenosis included percent diameter stenosis (%DS), minimum lumen diameter (MLD),
percent area stenosis (%AS), and minimum lumen area (MLA). For each patient, the mean of all matched
segments was calculated at the 2 time points. Clinical events at follow-up were documented.
R E S U L T S The PAV did not change signiﬁcantly (0.15  3.64%, p  0.72). The mean change in
TAVnorm was 47.36 143.24 mm3 (p 0.071), and the % change in TAV was 6.7% (p 0.029). The MLD
and MLA increased by 0.15 mm (0.09 to 0.24, p  0.039) and 0.52 mm2 (0.38 to 1.04, p  0.034)
respectively, which was accompanied by vessel enlargement, with 53% of the patients showing
expansive positive remodeling. Patients with clinical events had a larger TAVnorm at baseline (969.72
mm3 vs. 810.77 mm3, p  0.010).
CONC L U S I O N S MSCT can assess the progression of coronary atherosclerosis and may be used for
noninvasive monitoring of pharmacological interventions in coronary artery disease. (PROSPECT: An
Imaging Study in Patients With Unstable Atherosclerotic Lesions; NCT00180466) (J Am Coll Cardiol Img
2012;5:S28–37) © 2012 by the American College of Cardiology Foundation
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S29oronary atherosclerosis is a worldwide
pandemic disease and accounts for almost
17 million deaths annually (1). Although
quantitative coronary angiography (QCA)
has been used in the past to study the extent of the
disease (2), this technique can only depict the
contrast-enhanced lumen, whereas atherosclerotic
disease of the arterial wall does not necessarily result
in narrowing of the vessel lumen. Currently, the
preferred method to study atherosclerosis is by
intracoronary, cross-sectional imaging methods,
such as intravascular ultrasound (IVUS) (3). There
are numerous serial studies on atherosclerosis pro-
gression/regression by QCA and IVUS, including
randomized medical trials using imaged plaque
modification as surrogate endpoints. However, QCA
and IVUS are invasive and costly and are not free of
complications and thus are not used for routine
serial assessment of atherosclerosis.
On the other hand, multislice computed tomog-
raphy (MSCT) can assess coronary plaque in a
noninvasive manner. MSCT coronary angiography
has emerged as a noninvasive technique for the
detection of coronary artery disease and has dem-
onstrated good accuracy for the detection of coro-
nary artery stenosis (4,5). Furthermore, studies in
patients undergoing both IVUS and MSCT sup-
port the feasibility of MSCT to assess atheroscle-
rotic plaque burden, remodeling, eccentricity, and
calcified and noncalcified plaque in both stable and
unstable patients (6–8).
Although a few serial studies with MSCT have
been published (9–15), most prior analyses were
confined to a small segment of the coronary tree or
a specific subset of lesions (i.e., noncalcified). In the
present study, our objective was to study the natural
history of coronary atherosclerosis along the full
length of the coronary tree by MSCT and to assess
the serial changes in coronary plaque size, lumen
dimensions, and arterial remodeling.
M E T H O D S
Study population. We prospectively included pa-
ients who were enrolled at the Erasmus Medical
enter in the PROSPECT (Providing Regional
bservations to Study Predictors of Events in the
oronary Tree) study (16). PROSPECT was de-
igned to identify nonobstructing lesions with an
ncreased risk for future acute coronary events in
atients presenting with acute coronary syndromes
ACS) using IVUS and serological markers of
nflammation. ACS was defined as ST-segmentlevation myocardial infarction, non–ST-segment
levation myocardial infarction (troponin positive),
r unstable angina with ECG changes (troponin
egative). As a substudy of the multicenter study,
e additionally performed contrast-enhanced com-
uted tomography (CT) coronary angiography to
oninvasively evaluate the extent of coronary ath-
rosclerosis at baseline and at 3 years’ follow-up.
atients were considered for inclusion in the
SCT substudy only if they had a heart rate lower
han 70 beats/min during the MSCT acquisition
nd had no prior coronary bypass surgery. Exclusion
riteria included impaired renal function (serum
reatinine 120 mmol/l), contrast allergy, and ir-
egular heart rhythms. Levels of fasting lipids were
easured at baseline and follow-up. Med-
cation use (including statins) after dis-
harge was according to standard of care.
he institutional review board of our hos-
ital approved the study, and all patients
rovided written informed consent before
tudy participation.
MSCT acquisition. At baseline, all patients
underwent CT coronary angiography with
a 64-slice scanner (Sensation 64, Siemens
Medical Solutions, Forchheim, Germany).
Because patients in the acute phase of
ACS were already treated with intrave-
nous nitrates and beta-blockers, additional
medication before CT scan was not nec-
essary. Scan parameters were as follows: a
gantry rotation time of 330 ms, 32 2 slices
per rotation, 0.6-mm detector collimation,
spiral scan mode with a table feed of 3.8
mm per rotation, a tube voltage of 120 kV,
and tube current of 900 effective mAs.
Prospective ECG-triggered x-ray tube
modulation was not applied. A bolus of
100 ml of contrast material (400 mg/ml; Iomeron,
Bracco, Milan, Italy) was injected intravenously at 5
ml/s flow rate followed by a saline chaser. The
initiation of the scan was synchronized to the arrival of
contrast in the coronary arteries by a bolus-tracking
technique. The mean effective radiation dose was 14.0
0.8 mSv, using the dose-length product and a
conversion factor k (0.014 mSv/mGy/cm) (17).
Axial CT images were reconstructed with a slice
thickness of 0.75-mm and 0.4-mm increments
using a retrospective ECG gating algorithm to
obtain optimal, motion-free image quality. Optimal
datasets with the best image quality were recon-
structed mainly in the mid- to end-diastolic phase,
A B B
A N D
ACS
AS
CT
DS
ECG
IQR
IVUS
LDL
MLA
MLD
diame
MSCT
tomog
PAV
volum
QCA
angio
TAVusing a medium-smooth convolution kernel.R E V I A T I O N S
A C R O N YM S
acute coronary syndrome
area stenosis
computed tomography
diameter stenosis
electrocardiogram
interquartile range
 intravascular ultrasound
low-density lipoprotein
minimum lumen area
minimum lumen
ter
multislice computed
raphy
percent atheroma
e
quantitative coronary
graphy
o
m
s
i
e
i
i
f
o
t
i
b
v
l
0
t
w
e
w
2
w
d
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 3 , S U P P L S , 2 0 1 2
M A R C H 2 0 1 2 : S 2 8 – 3 7
Papadopoulou et al.
Natural History of Coronary Atherosclerosis by CTA
S30The follow-up scan was performed after 3 years,
using a 64-slice dual-source CT scanner (Somatom
Definition, Siemens Medical Solutions, Forchheim,
Germany). Sublingual nitroglycerin was adminis-
tered before the scan (0.4 mg/dose) provided that
there were no contraindications, and pre-scan beta-
blockers were given to patients with high heart rates70
beats/min. The CT angiographic scan parameters
were as follows: 32  2  0.6 mm collimation with
z-flying focal spot for both detectors, gantry rota-
tion time of 330 ms, tube voltage of 120 kV, and
tube current of 320 to 412 mAs per rotation. A
bolus of iodinated contrast material (370 mg/ml;
Ultravist, Schering, Berlin, Germany), which varied
between 60 and 100 ml, depending on the expected
scan time, was injected intravenously (flow rate 5.5
ml/s) followed by a 40-ml saline chaser at the same
injection rate. A bolus tracking technique was used
to synchronize the arrival of contrast in the coronary
arteries and the start of the acquisition. A spiral
scan protocol with prospective ECG-triggered
x-ray tube modulation and variable table feed de-
pending on the heart rate was applied. The esti-
mated mean effective radiation dose was 10.0  3.2
mSv. Axial images were reconstructed using retro-
spective ECG gating, with a slice thickness of 0.75-
mm, slice increment of 0.4-mm, and medium-to-
Figure 1. Multislice Computed Tomography Angiography Analy
Example of vessel analyzed at baseline (A) and 3-year follow-up (B)
cross-sections shown at the bottom of the ﬁgure (from proximal to
tently from baseline to follow-up in the 5 cross-sections analyzed.smooth convolution kernel. Optimal datasets with
the best image quality were reconstructed mainly in
the mid- to end-diastolic phase.
MSCT analysis. All datasets were transferred to an
ffline workstation for analysis using a semiauto-
ated plaque analysis software (QAngioCT Re-
earch Edition version 1.1.8, Medis Medical Imag-
ng Systems, Leiden, the Netherlands) (18). An
xperienced observer blinded to the sequence of
maging evaluated the scans. Planimetry of the
nner lumen and outer vessel areas was performed
ollowing a stepwise approach. First, a centerline
riginating from the ostium was automatically ex-
racted; then straightened multiplanar reformatted
mages were generated, and the lumen and vessel
orders were detected longitudinally on 4 different
essel views by the software. On the basis of these
ongitudinal contours, cross-sectional images at
.5-mm intervals were calculated in order to create
ransversal lumen and vessel wall contours, which
ere examined and, if necessary, adjusted by an
xperienced observer (Fig. 1). The settings for
indow level and width were fixed at 740 HU and
20 HU, respectively. Gradient magnitude images,
hich are derived from the MSCT images and
isplay the degree of CT density change, were used
both panels, 5 lines indicate the location in the vessel of the
al). In this lesion, the plaque burden (PB, %) decreases consis-sis
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S31to facilitate detection of lumen and vessel wall
borders.
All 3 vessels were assessed in every patient using
the modified 17-segment American Heart Associ-
ation model for coronary segment classification
(19). Only the major epicardial vessels were consid-
ered for analysis (segments 1, 2, 3, 6, 7, 8, 11, 13,
and 15). All anatomically available segments with-
out implanted stents were examined; the segments
of poor quality due to stack or movement artifacts
or extreme calcification were excluded from analy-
sis, as well as the segments distal to stents.
The following parameters were derived per seg-
ment: the mean lumen area, the mean vessel area,
the mean percent plaque burden, the minimum and
maximum lumen diameter, and the minimum and
maximum lumen area. The mean areas were the
averaged measurements of all cross-sections for
each segment. The mean plaque area was calculated
by subtracting mean lumen area from mean vessel
area, and the plaque volume was calculated for every
segment by using the mean segment length from
the 2 time points (3). Furthermore, the composition
of each coronary segment was semiquantitatively
evaluated: Each individual cross-section was binary
labeled for the presence of calcium (yes/no), and the
degree of calcification was assessed as a percent of
the segment length (number of frames containing
calcium/total number of frames in the segment). To
examine inter- and intra-observer variability, a sec-
ond reader re-analyzed 7 randomly selected seg-
ments, and the first reader re-analyzed 11 randomly
selected segments 3 months after his/her original
analysis.
Study imaging endpoints. The following parameters
ere calculated per segment and per patient.
QCA-LIKE PARAMETERS
Minimum lumen diameter (MLD): the nar-
rowest lumen diameter within each segment
Percent diameter stenosis (%DS): [(reference
iameter – MLD)/reference diameter]  100%.
he reference diameter was the largest (maximal)
umen diameter within each segment.
For each patient, the average %DS of all seg-
ents at baseline and follow-up was calculated.
rom these values, the change from baseline was
alculated for each patient. In addition, the per-
atient average of MLD (mm) of all segments was
alculated at baseline and at follow-up for the
atching segments. The average change in MLD
t baseline was calculated for each patient using
hese values. Clinically relevant regression or pro-
ression was defined as a nominal change (from ebaseline to 3 years) of 10% for %DS and 0.2 mm for
MLD (20).
IVUS-LIKE PARAMETERS
Percent atheroma volume (PAV): [(total vessel
volume – total lumen volume)/total vessel volume] 
100%
Total atheroma volume (TAV): total vessel
volume – total lumen volume
Normalized TAV (TAVnorm): [(total vessel
volume – total lumen volume)/segment length] 
mean segment length in the population. Normal-
ization for segment length provides equal weighting
of each patient in the calculation of atheroma
volume (3).
Percentage change in TAV (% change in
TAV): [(TAV follow-up  TAV baseline)/TAV
aseline]  100%
Minimum lumen area (MLA): the narrowest
umen area in each segment
Percent area stenosis (%AS): [(reference lumen
rea  MLA)/reference lumen area]  100. The
reference lumen area used was the largest (maximal)
lumen area within each segment.
For each patient, the average %AS of all seg-
ments at baseline and follow-up was calculated.
From these values, the change from baseline was
calculated for each patient. Also, the per-patient
average of MLA (mm2) of all segments was calcu-
ated at baseline and at follow-up for the corre-
ponding segments. The average change in MLA
rom baseline was calculated for each patient using
hese values.
Clinically relevant regression or progression in
AV was defined as a change (from baseline to
ollow-up) of1% for PAV, which was the thresh-
ld for significant regression previously detected
nder intensive lipid-lowering treatment (21).
Coronary remodeling. As recommended for serial
studies (3), remodeling was assessed as vessel area at
follow-up minus vessel area at baseline. An increase
in vessel area was considered positive remodeling,
no change in vessel area was considered absence of
remodeling, and a decrease in vessel area was
considered negative remodeling. Furthermore, seg-
ments with positive remodeling were subdivided as
expansive (over-compensatory) when vessel area/
atheroma 1 or incomplete when vessel area/
atheroma was between 0 and 1.
Clinical endpoints. Clinical event data were collected
hroughout the duration of the study at regular
ollow-up intervals and registered in the hospital
linical database. Major adverse cardiovascular
vents were defined as the composite of cardiac
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S32death, cardiac arrest, myocardial infarction, and
rehospitalization due to unstable or progressive
angina (16).
Statistical analysis. Continuous variables are pre-
ented as mean  SD and median (interquartile
ange [IQR]), as indicated. Categorical variables are
resented as counts and percentages. Continuous
ariables between the 2 different time points were
ompared by the paired samples t test if the data
ere normally distributed or the Wilcoxon signed
ank test for non-normal data (as tested by the
olmogorov-Smirnov test). A p value 0.05 was
onsidered significant. Statistical analyses were per-
ormed with use of SPSS version 17.0 software
SPSS, Chicago, Illinois).
Flow of Study Patients
Table 1. Baseline Patient Characteristics (n  32)
Age, yrs 53 10
Male 26 (81)
Risk factors
Hypertension 9 (28)
Hypercholesterolemia 11 (34)
Diabetes mellitus 3 (9)
Current smoking 18 (56)
Family history of coronary artery disease 19 (59)
Obesity 3 (9)
Clinical condition at enrollment
Unstable angina 9 (28)
Acute myocardial infarction 23 (72)
Cholesterol
Total, mg/dl 180 41
Low-density lipoprotein, mg/dl 124 42
High-density lipoprotein, mg/dl 43 12
Triglycerides, mg/dl 139 87
Values are mean  SD or n (%).mputed tomography coronary angiography.R E S U L T S
Baseline clinical and angiographic characteristics.
From the original cohort of 47 patients undergoing
baseline CTCA, 36 (77%) underwent a follow-up
CTCA at 3 years. The follow-up scan was under-
taken at a mean of 38  3 months (median 39
months, IQR: 37 to 40 months) after the initial
examination. The patients’ baseline characteristics
are shown in Table 1, and their disposition is shown
in Figure 2. In total, 129 segments from 32 patients
were analyzed. The mean length of analysis was
22.0 9.5 mm per segment and 89.0 40.5 mm per
patient. The proportion of calcified frames per
segment at baseline was 6  12% versus 11  17%
t follow-up (p  0.001).
All patients at discharge received standard-of-
care medical therapy, including statins (29 patients
received atorvastatin 40 mg/day, 2 patients received
simvastatin 40 mg/day, and 1 patient received
rosuvastatin 10 mg/day). One patient discontinued
statin use due to an adverse effect. The mean total
cholesterol was 180  41 mg/dl at baseline and 150 
0 mg/dl at follow-up. The mean low-density
ipoprotein (LDL) level was 124  42 mg/dl at
aseline and 85 13 mg/dl at follow-up. The mean
igh-density lipoprotein level was 43 12 mg/dl at
aseline and 46 15 mg/dl at follow-up. The mean
riglycerides value was 139  87 mg/dl at baseline
nd 114  76 mg/dl at follow-up.
MSCT QCA-like analysis. MEASURES OF STENOSIS
ER SEGMENT. From baseline to 3-year follow-up,
there was an increase in lumen dimensions, result-
ing in a decrease in the relative lumen stenosis
(Table 2). In particular, there was a significant
increase in MLD by 0.11 mm (IQR: 0.15 to 0.27
mm; p  0.010), and this was accompanied by a
decrease in %DS of 1.05% (IQR 7.15% to
5.08%; p  0.257).
There were no clinically relevant changes in MLD
(0.2mm) in 45.7% of the segments, whereas 32.6%
segments showed regression (0.2-mm increase in
MLD) and 21.7% showed progression (0.2mm
decrease in MLD) (Online Appendix). There was no
statistically significant difference in the prevalence of
progressors and regressors.
There were also no clinically relevant changes in
%DS (10%) in most of the segments (70.5%),
whereas 17.8% of the segments showed regression
(10% decrease in %DS) and 11.6% showed pro-
gression (10% increase in %DS). There was no
statistically significant difference in the prevalenceFigure 2.of progressors and regressors.
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S33MEASURES OF STENOSIS PER PATIENT. Similar
ndings were found on a per-patient level (i.e., an
ncrease in lumen diameter and relative decrease in
tenosis). The MLD increased by 0.15 mm (IQR:
0.09 to 0.24 mm; p  0.039) and the %DS
decreased by 0.83% (IQR: –6.3 to 3.16; p 0.326).
There were no clinically relevant changes in
MLD (0.2 mm) in 46.9% of the patients, whereas
37.5% of patients showed regression (0.2 mm
increase in MLD) and 15.6% showed progression
(0.2 mm decrease in MLD). There was no
statistically significant difference in the prevalence
of progressors and regressors.
There were also no clinically relevant changes in
%DS (10%) in most of the patients (87.5%),
whereas considerably fewer patients (9.4%) showed
regression (10 decrease in %DS), and 3.1%
showed progression (10% increase in %DS).
There was no statistically significant difference in
the prevalence of progressors and regressors.
MSCT IVUS-like analysis. PLAQUE VOLUMETRIC
MEASURES PER SEGMENT. From baseline to 3-year
ollow-up, the PAV did not change significantly,
hereas there was a significant relative percentage
hange in TAV by 5.8 18.0% (p 0.001) (Table 3).
here were no clinically relevant changes in PAV
1%) in 24.0% of the segments, whereas 38.8%
egments showed regression (1% decrease in
AV) and 37.2% showed progression (1% in-
rease in PAV) (Online Appendix). There was no
tatistically significant difference in the prevalence
Table 2. MSCT QCA-Like Analysis
Baseline
Baseline and follow-up quantitative parameters
analyzed per segment (n  129)
Minimum lumen diameter (mm)
Mean SD 2.49 0.61
Median (IQR) 2.36 (2.04–2.85)
% Diameter stenosis
Mean SD 28.3 10.0
Median (IQR) 27.6 (21.1–35.0)
Baseline and follow-up quantitative parameters
analyzed per patient (n  32)
Minimum lumen diameter (mm)
Mean SD 2.51 0.52
Median (IQR) 2.42 (2.09–2.87)
% Diameter stenosis
Mean SD 28.1 6.6
Median (IQR) 28.6 (23.8–32.2)
*Wilcoxon signed rank test; †paired t test.
IQR  interquartile range; MSCT  multislice computed tomography; QCAf progressors and regressors.PLAQUE VOLUMETRIC MEASURES PER PATIENT. At
3-year follow-up, there was no significant change in
PAV (mean difference 0.15  3.64 mm3; p 
.819), whereas there was a trend toward increase in
ormalized TAV of 47.36  143.24 mm3 (p 
.071). Similarly, there was a significant percentage
hange in TAV by 6.7  16.6% (p  0.029).
There were no clinically relevant changes in PAV
1%) in 21.8% of the patients, whereas 34.4%
atients showed regression (1% decrease in PAV)
nd 43.8% showed progression (1% increase in
AV). There was no statistically significant differ-
nce in the prevalence of progressors and regressors.
CORONARY REMODELING. Overall, the plaque in-
rease occurred without compromising the lumen
nd was compensated for by an increase in vessel
ize (mostly expansive positive remodeling) (Table 4).
pproximately one third of the patients/segments
howed negative remodeling.
Clinical events. There were 8 clinical events in this
ohort during the length of the study. Five events
ere related to the stented segment (3 patients with
tent thrombosis, myocardial infarction, and repeat
evascularization and 2 with repeat revascularization
ith angina), and the other 3 patients developed
rogressive angina. Of note, these patients present-
ng with clinical events had larger normalized TAV
t baseline (969.72 vs. 810.77 mm3; p 0.010). We
found no difference between patients with and
without events regarding plaque progression (i.e.,
Follow-Up Change p Value
n (%) With
Regression
82 (64)
2.58 0.72 0.09 0.42
2.41 (2.01–3.09) 0.11 (–0.15 to 0.27) 0.010*
71 (55)
27.6 11.1 –0.68 10.03
26.0 (20.7–35.0) –1.05 (–7.15 to 5.08) 0.257*
23 (72)
2.63 0.62 0.11 0.32
2.47 (2.23–3.09) 0.15 (–0.09 to 0.24 0.039*
17 (53)
27.0 7.5 –1.13 6.39 0.326†
26.4 (20.4–32.2) –0.83 (–6.30 to 3.16)
uantitative coronary angiography.change from baseline in PAV or TAV).
a
a
l
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S34Observer variability. For the 11 segments included
in the intra-observer analysis, there were a total of
523 cross-sections analyzed. The mean differences
were small for both lumen (0.16  0.93 mm2)
nd vessel areas (0.11  1.17 mm2). The corre-
lations between the original and subsequent analysis
were high (r  0.98 for lumen areas, r  0.98 for
vessel areas). For the 7 segments included in the
inter-observer analysis, there were a total of 335
cross-sections analyzed. The mean differences were
ike Analysis
Baseline Fol
plaque quantitative parameters
egment (n  129)
lume (%)
56.7 7.3 56.7
58.0 (52.0–63.0) 58.0 (5
me (mm3)
217.2 134.0 224.7
183.4 (130.2–280.0) 194.2 (1
theroma volume
lumen quantitative parameters
egment (n  129)
a (mm2)
5.16 2.68 5.65
4.38 (3.27–6.34) 4.55 (3
47.6 14.1 46.4
47.8 (37.4–57.9) 44.8 (3
plaque quantitative parameters
atient (n  32)
lume (%)
56.0 7.0 55.9
56.6 (50.0–61.5) 57.9 (5
eroma volume (mm3)
850.5 155.7 897.9
833.7 (753.4–930.1) 892.0 (7
theroma volume
lumen quantitative parameters
atient (n  32)
a (mm2)
5.26 2.26 5.83
4.66 (3.48–6.66) 4.84 (3
47.3 9.4 45.5
48.5 (41.8–43.5) 45.5 (3
t; †paired t test; ‡1-sample t test.
ltrasound; other abbreviations as in Table 2.also small for both lumen (0.01  1.19 mm2) andvessel areas (0.08  1.31 mm2). Close correla-
tions between the original analysis and re-analysis
were found (r  0.97 for lumen, r  0.98 for vessel
reas). The repeatability results are very much in
ine with previous IVUS reports.
D I S C U S S I O N
The purpose of this exploratory substudy was to
assess the natural history of coronary atherosclerosis
Up Change p Value
n (%) With
Regression
59 (46)
.7 –0.07 4.34
62.0) 0.0 (–3.0 to 3.0) 0.790*
49 (38)
36.9 7.52 42.54
–274.4) 7.08 (–14.38 to 29.01) 0.019*
49 (38)
5.84 17.98 0.001‡
4.55 (–4.27 to 20.96)
82 (64)
.21 0.49 1.84
7.49) 0.44 (–0.73 to 1.15) 0.009*
70 (54)
5.2 –1.18 13.86 0.336†
57.6) –1.58 (–10.6 to 7.3)
15 (47)
.3 –0.15 3.64 0.819†
61.3) 0.72 (–2.75 to 2.41)
11 (34)
75.4 7.36 143.24 0.071†
–993.1) 31.39 (–42.08 to 163.06)
11 (34)
6.7 16.55 0.029‡
3.54 (–4.27 to 20.96)
22 (69)
.78 0.57 1.43
7.73) 0.52 (–0.38 to 1.04) 0.034*
17 (53)
0.6 –1.72 8.96 0.286†
52.8) –0.68 (–9.31 to 3.92)Table 3. MSCT IVUS-L
low-
Baseline and follow-up
analyzed per s
Percent atheroma vo
Mean SD  7
Median (IQR) 1.0–
Total atheroma volu
Mean SD  1
Median (IQR) 29.6
% Change in total a
Mean SD
Median (IQR)
Baseline and follow-up
analyzed per s
Minimum lumen are
Mean SD  3
Median (IQR) .17–
% Area stenosis
Mean SD  1
Median (IQR) 7.1–
Baseline and follow-up
analyzed per p
Percent atheroma vo
Mean SD  7
Median (IQR) 0.4–
Normalized total ath
Mean SD  1
Median (IQR) 36.0
% Change in total a
Mean SD
Median (IQR)
Baseline and follow-up
analyzed per p
Minimum lumen are
Mean SD  2
Median (IQR) .98–
% Area stenosis
Mean SD  1
Median (IQR) 6.5–
*Wilcoxon signed rank tes
IVUS  intravascular uby MSCT in patients with an ACS who were
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S35treated with percutaneous coronary intervention
and contemporary medical therapy.
The main findings of this report are as follows:
despite standard-of-care treatment, the atheroma
size in untreated non-culprit lesions increased over
3 years, compensated for by an increase in the vessel
size (positive expansive remodeling) and without
compromising the lumen. Our MSCT findings on
atherosclerosis progression fit closely to the regres-
Table 4. Coronary Remodeling Endpoints
Per segment (n  129)
Serial remodeling (mm2) 0.82 2.83*
Positive remodeling
Expansive 61 (47)
Incomplete 23 (18)
Negative remodeling 45 (35)
Per patient (n  32)
Serial remodeling (mm2) 1.10 2.68†
Positive remodeling
Expansive 17 (53)
Incomplete 6 (19)
Negative remodeling 9 (28)
Values are mean  SD and n (%). *p  0.001; †p  0.027.
Figure 3. Association Between Mean Low-Density Lipoprotein C
Percent Atheroma Volume for Several Intravascular Ultrasound
A-Plus  Avasimibe and Progression of Lesions on Ultrasound (22);
vascular Ultrasound-Derived Coronary Atheroma Burden (21); CAME
of Thrombosis (23); ILLUSTRATE  Investigation of Lipid Level Man
sclerosis by CETP Inhibition and HDL Elevation (24); REVERSAL  Reve
Study of Coronary Atheroma by Intravascular Ultrasound: Effect of R
Reduce Atherosclerosis Development Involving Administration of Ri
Providing Regional Observations to Study Predictors of Events in the
Modiﬁed from Nissen et al. (21).sion line of the relationship between mean LDL
under treatment and median change in PAV from
previous IVUS studies (Fig. 3).
Plaque burden and coronary events. IVUS studies
(28) have demonstrated that there is a direct associa-
tion between the burden of coronary atherosclerosis,
its progression, and the presence of clinical events at
follow-up. Similarly, in the main PROSPECT study,
lesions with plaque burden 70% were shown to be
trongly associated with future clinical events (16).
ur data are in accordance with these findings,
ecause the patients presenting with clinical events
ad greater amount of plaque at baseline. This
bservation could contribute to the potential devel-
pment of prediction models based on atheroscle-
otic plaque burden.
Coronary remodeling. Motoyama et al. (29) and
offmann et al. (6) described that the plaques in
atients with ACS have positive remodeling and are
ssociated with events. Consistent with the original
escription by Glagov et al. (30), our MSCT data
howed that arteries enlarge as atherosclerosis pro-
resses. Previous serial IVUS reports have demon-
trated that atheroma burden does not limit com-
esterol Levels and Median Change in
dies
EROID  A Study to Evaluate the Effect of Rosuvastatin on Intra-
 Comparison of Amlodipine vs. Enalapril to Limit Occurrences
ent Using Coronary Ultrasound to Assess Reduction of Athero-
of Atherosclerosis With Aggressive Lipid-Lowering (25); SATURN 
vastatin versus Atorvastatin (26); STRADIVARIUS  Strategy to
abant—The Intravascular Ultrasound Study (27); PROSPECT 
ronary Tree (multislice computed tomography substudy).hol
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S36pensatory remodeling (31), whereas there is a broad
spectrum of serial remodeling responses in coronary
atherosclerosis (32,33).
Importantly, arterial remodeling changes closely
relate to changes in PAV, which is the most
common primary IVUS endpoint. In the absence of
actual change in plaque volume, positive remodel-
ing could reduce PAV, whereas negative remodel-
ing would increase PAV.
Progression/regression analysis using MSCT. MSCT
can assess coronary atherosclerosis by combining
the 2 “worlds” of QCA-like and IVUS-like param-
eters. To our knowledge, this comprehensive ap-
proach used in our study was not performed in
previous MSCT studies. Furthermore, the follow-up
time of our report (median 39 months) is the
longest duration to date reported in progression/
regression studies.
Previous papers have shown that MSCT is com-
parable to QCA angiography regarding lumen ste-
nosis assessment (4,5); similarly, IVUS and MSCT
comparative studies (6–8) have shown that the
MSCT can reasonably evaluate atherosclerotic
plaque size, remodeling, eccentricity, and composi-
tion, despite the acknowledged limitations of the
technique. Voros et al. (8) suggested that quantita-
tive MSCT angiography could be acceptably used
in population-based approaches, given the small
mean differences between MSCT and IVUS-virtual
histology measurements.
Interestingly, our results closely fit the regression
line in the classical graph depicting the relation
between mean LDL levels and median change in
PAV for several previous IVUS progression/
regression studies.
Most prior IVUS studies have used PAV as the
primary endpoint; however, the percentage change
in TAV may be more suitable for MSCT studies,trials. Circulation 1991;84:412–23. tern Med 2010;152but the full coronary tree can be assessed. Con-
versely, considering the resolution and reproducibil-
ity of MSCT, the minute changes in PAV observed
in IVUS studies may be more difficult to detect.
Study limitations. This is a single-center feasibility
study that comprised a selected small population of
patients presenting with ACS, and the findings may
be different in stable patients. Due to the small
sample size, multivariate analysis was not per-
formed. Furthermore, the baseline CT scans were
obtained with an earlier generation 64-slice CT
scanner, which may have produced inferior image
quality compared with dual-source CT equipment
used during follow-up. Nevertheless, we were able
to detect changes of coronary atherosclerosis during
the follow-up period. Because this was not a drug
efficacy study, the patients received contemporary
medical therapy at the discretion of the treating
physician; however, the vast majority of patients
(91%) received 40 mg of atorvastatin, which made
the statin use relatively uniform. Finally, radiation
exposure during MSCT coronary angiography still
remains a matter of concern. Nonetheless, signifi-
cant reductions of radiation dose are currently being
achieved by implementation of dose-saving tech-
niques (34), which result in effective dose less than
the 5 mSv of the invasive coronary angiography.
C O N C L U S I O N S
MSCT provides insightful information on the nat-
ural history of coronary atherosclerosis and may be
used for noninvasive monitoring of pharmacological
interventions for coronary artery disease.
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